163 related articles for article (PubMed ID: 24195794)
1. Novel AGLP-1 albumin fusion protein as a long-lasting agent for type 2 diabetes.
Kim YM; Lee SM; Chung HS
BMB Rep; 2013 Dec; 46(12):606-10. PubMed ID: 24195794
[TBL] [Abstract][Full Text] [Related]
2. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo.
Kim JG; Baggio LL; Bridon DP; Castaigne JP; Robitaille MF; Jetté L; Benquet C; Drucker DJ
Diabetes; 2003 Mar; 52(3):751-9. PubMed ID: 12606517
[TBL] [Abstract][Full Text] [Related]
3. Preparation and characterization of a novel exendin-4 human serum albumin fusion protein expressed in Pichia pastoris.
Huang YS; Chen Z; Chen YQ; Ma GC; Shan JF; Liu W; Zhou LF
J Pept Sci; 2008 May; 14(5):588-95. PubMed ID: 17994612
[TBL] [Abstract][Full Text] [Related]
4. The N-terminal alanine-extended GLP-1/IgG-Fc fusion protein confers resistance to DPP-IV and reduces serum glucose level in db/db mice.
Chung HS; Oh JY; Yoo SB; Lee SM; Cho HS
Regul Pept; 2011 Oct; 170(1-3):1-3. PubMed ID: 21621561
[TBL] [Abstract][Full Text] [Related]
5. Albumin-binding domain extends half-life of glucagon-like peptide-1.
Tan H; Su W; Zhang W; Zhang J; Sattler M; Zou P
Eur J Pharmacol; 2021 Jan; 890():173650. PubMed ID: 33049303
[TBL] [Abstract][Full Text] [Related]
6. Effects of GW002, a novel recombinant human glucagon-like peptide-1 (GLP-1) analog fusion protein, on CHO recombinant cells and BKS-db mice.
Ji WW; Yu DA; Fan M; You M; Lu Y; Li EB; Xie N; Yan SS
Acta Diabetol; 2017 Jul; 54(7):685-693. PubMed ID: 28424924
[TBL] [Abstract][Full Text] [Related]
7. Transferrin fusion technology: a novel approach to prolonging biological half-life of insulinotropic peptides.
Kim BJ; Zhou J; Martin B; Carlson OD; Maudsley S; Greig NH; Mattson MP; Ladenheim EE; Wustner J; Turner A; Sadeghi H; Egan JM
J Pharmacol Exp Ther; 2010 Sep; 334(3):682-92. PubMed ID: 20498254
[TBL] [Abstract][Full Text] [Related]
8. Development, characterization, and evaluation of a fusion protein of a novel glucagon-like peptide-1 (GLP-1) analog and human serum albumin in Pichia pastoris.
Gao Z; Bai G; Chen J; Zhang Q; Pan P; Bai F; Geng P
Biosci Biotechnol Biochem; 2009 Mar; 73(3):688-94. PubMed ID: 19270384
[TBL] [Abstract][Full Text] [Related]
9. Fc fusion to glucagon-like peptide-1 inhibits degradation by human DPP-IV, increasing its half-life in serum and inducing a potent activity for human GLP-1 receptor activation.
Kim DM; Chu SH; Kim S; Park YW; Kim SS
BMB Rep; 2009 Apr; 42(4):212-6. PubMed ID: 19403044
[TBL] [Abstract][Full Text] [Related]
10. Engineered beta-cells secreting dipeptidyl peptidase IV-resistant glucagon-like peptide-1 show enhanced glucose-responsiveness.
Islam MS; Rahman SA; Mirzaei Z; Islam KB
Life Sci; 2005 Jan; 76(11):1239-48. PubMed ID: 15642594
[TBL] [Abstract][Full Text] [Related]
11. A novel exendin-4 human serum albumin fusion protein, E2HSA, with an extended half-life and good glucoregulatory effect in healthy rhesus monkeys.
Zhang L; Wang L; Meng Z; Gan H; Gu R; Wu Z; Gao L; Zhu X; Sun W; Li J; Zheng Y; Dou G
Biochem Biophys Res Commun; 2014 Mar; 445(2):511-6. PubMed ID: 24565847
[TBL] [Abstract][Full Text] [Related]
12. Intestinal Sodium Glucose Cotransporter 1 Inhibition Enhances Glucagon-Like Peptide-1 Secretion in Normal and Diabetic Rodents.
Oguma T; Nakayama K; Kuriyama C; Matsushita Y; Yoshida K; Hikida K; Obokata N; Tsuda-Tsukimoto M; Saito A; Arakawa K; Ueta K; Shiotani M
J Pharmacol Exp Ther; 2015 Sep; 354(3):279-89. PubMed ID: 26105952
[TBL] [Abstract][Full Text] [Related]
13. Expression and bioactivity of recombinant human serum albumin and dTMP fusion proteins in CHO cells.
Ru Y; Zhi D; Guo D; Wang Y; Li Y; Wang M; Wei S; Wang H; Wang N; Che J; Li H
Appl Microbiol Biotechnol; 2016 Sep; 100(17):7565-75. PubMed ID: 27115755
[TBL] [Abstract][Full Text] [Related]
14. One-step purification of a fusion protein of glucagon-like peptide-1 and human serum albumin expressed in pichia pastoris by an immunomagnetic separation technique.
Chen J; Bai G; Cao Y; Gao Z; Zhang Q; Zhu Y; Yang W
Biosci Biotechnol Biochem; 2007 Nov; 71(11):2655-62. PubMed ID: 17986790
[TBL] [Abstract][Full Text] [Related]
15. A novel GLP-1 analog exhibits potent utility in the treatment of type 2 diabetes with an extended half-life and efficient glucose clearance in vivo.
Li Y; Xu W; Tang L; Gong M; Zhang J
Peptides; 2011 Jul; 32(7):1408-14. PubMed ID: 21664938
[TBL] [Abstract][Full Text] [Related]
16. Identifying glucagon-like peptide-1 mimetics using a novel functional reporter gene high-throughput screening assay.
Chen J; Bai G; Yang Y; Geng P; Cao Y; Zhu Y
Peptides; 2007 Apr; 28(4):928-34. PubMed ID: 17267075
[TBL] [Abstract][Full Text] [Related]
17. Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
Green BD; Gault VA; Irwin N; Mooney MH; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
Biol Chem; 2003 Dec; 384(12):1543-51. PubMed ID: 14719796
[TBL] [Abstract][Full Text] [Related]
18. Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1.
Burcelin R; Dolci W; Thorens B
Metabolism; 1999 Feb; 48(2):252-8. PubMed ID: 10024091
[TBL] [Abstract][Full Text] [Related]
19. Addition of a cysteine to glucagon-like peptide-1 (GLP-1) conjugates GLP-1 to albumin in serum and prolongs GLP-1 action in vivo.
Wu YL; Huang J; Xu J; Liu J; Feng Z; Wang Y; Lai Y; Wu ZR
Regul Pept; 2010 Sep; 164(2-3):83-9. PubMed ID: 20570598
[TBL] [Abstract][Full Text] [Related]
20. Efficient expression of stable recombinant human insulin-like growth factor-1 fusion with human serum albumin in Chinese hamster ovary cells.
Wan A; Xu D; Liu K; Peng L; Cai Y; Chen Y; He Y; Yang J; Jin J; Li H
Prep Biochem Biotechnol; 2017 Aug; 47(7):678-686. PubMed ID: 28281882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
